Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial

Axel Bex*, Peter Mulders, Michael Jewett, John Wagstaff, Johannes V. van Thienen, Christian U. Blank, Roland van Velthoven, Maria del Pilar Laguna, Lori Wood, Harm H. E. van Melick, Maureen J. Aarts, J. B. Lattouf, Thomas Powles, Igle Jan de Jong, Sylvie Rottey, Bertrand Tombal, Sandrine Marreaud, Sandra Collette, Laurence Collette, John Haanen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)164-170
Number of pages7
JournalJAMA Oncology
Volume5
Issue number2
DOIs
Publication statusPublished - Feb 2019
EventESMO 2017 Congress - European Society for Medical Oncology - IFEMA - Feria de Madrid, Madrid, Spain
Duration: 8 Sep 201712 Sep 2017
https://healthmanagement.org/c/hospital/event/esmo-2017-congress-european-society-for-medical-oncology

Keywords

  • PLANNED NEPHRECTOMY
  • TARGETED THERAPY
  • RADICAL NEPHRECTOMY
  • INTERFERON-ALPHA
  • CANCER
  • SURVIVAL
  • MORBIDITY
  • MORTALITY
  • RESECTION
  • EFFICACY

Cite this

Bex, A., Mulders, P., Jewett, M., Wagstaff, J., van Thienen, J. V., Blank, C. U., van Velthoven, R., Laguna, M. D. P., Wood, L., van Melick, H. H. E., Aarts, M. J., Lattouf, J. B., Powles, T., de Jong, I. J., Rottey, S., Tombal, B., Marreaud, S., Collette, S., Collette, L., & Haanen, J. (2019). Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial. JAMA Oncology, 5(2), 164-170. https://doi.org/10.1001/jamaoncol.2018.5543